An article in the European Medical Journal highlights groundbreaking preclinical research demonstrating that Neratinib, an existing FDA-approved drug primarily used for HER2-positive breast cancer, shows significant potential in combating vascular inflammation and atherosclerosis. The study, initially published in *Circulation Research*, revealed that Neratinib markedly reduced vascular inflammation and the progression of atherosclerosis in both human endothelial cell systems and *Ldlr-/-* mouse models. Crucially, the anti-inflammatory effects of Neratinib were found to be independent of its classical target, HER2/ERBB2 inhibition. Instead, researchers discovered that Neratinib directly binds to and suppresses the activation of apoptosis signal-regulating kinase 1 (ASK1), identifying a novel mechanism for its therapeutic action in cardiovascular disease. This suggests a potential new pathway for addressing the residual inflammatory risk in atherosclerotic cardiovascular diseases that current lipid-lowering therapies, such as statins, do not fully mitigate. Furthermore, the research indicated that combining Neratinib with rosuvastatin, a standard lipid-lowering drug, produced superior anti-atherosclerotic effects compared to statin monotherapy in the mouse models. This synergistic effect suggests a promising strategy for future therapeutic interventions. Given the high prevalence of cardiovascular diseases and atherosclerosis in India, this preclinical discovery holds significant relevance for an Indian audience, offering hope for new treatment avenues. While these findings are promising, they are currently preclinical and necessitate further clinical trials to evaluate efficacy and safety in humans.